Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
10 mM dNTP Mixture for DNA Synthesis
2026-08-26
The 10 mM dNTP mixture is an equimolar 2'-deoxyribonucleoside-5'-triphosphate mixture containing dATP, dCTP, dGTP, and dTTP at 10 mM each. Its pH 7.0 formulation supports PCR, qPCR, sequencing, and other DNA synthesis workflows when stored at -20°C or below and protected from repeated freeze-thaw cycles.
-
Angiotensin Peptides Enhance SARS-CoV-2 Receptor Binding
2026-08-26
A 2025 study found that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to AXL, with activity shaped by peptide length, terminal residues, and tyrosine modification. The work connects renin-angiotensin system biology with viral-receptor biochemistry while emphasizing that enhanced binding is not equivalent to demonstrated infection or disease causation.
-
In Vitro Drug Response: Lessons from Schwartz
2026-08-25
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. This framework supports better time-resolved assay design and more cautious interpretation of targeted therapy experiments.
-
Oligomycin A as an Immunometabolic Probe
2026-08-25
Oligomycin A is a mitochondrial ATP synthase inhibitor that connects respiratory control with macrophage immunometabolism. This guide explains how to use it as an orthogonal perturbation when studying the CH25H–25HC–AMPKα–STAT6 axis and cancer-cell metabolic adaptation.
-
REV1–DHX36 Coordination of G4 Tolerance
2026-08-24
Ketkar and colleagues identify a direct interaction between the REV1 C-terminal domain and the G-quadruplex helicase DHX36 that coordinates G4 unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The study provides a two-tier model for replication tolerance and clarifies how persistent G4 stabilization activates ATM/ATR signaling without establishing a direct therapeutic role for ATM inhibition.
-
GDC-0068 (RG7440) for Spatial AKT Research
2026-08-24
GDC-0068 (RG7440) combines pan-AKT coverage with a practical workflow for separating pathway suppression from feedback signaling. Use it to connect PI3K/Akt/mTOR activity, proliferation, cell-cycle state, apoptosis, and spatially resolved mTORC1 biology in genetically defined cancer models.
-
Enzalutamide, Myeloid Suppression, and Tumor Progression
2026-08-23
Consiglio and colleagues show that androgen receptor blockade can promote tumor progression through AR-expressing host myeloid cells, even when tumor-cell AR is absent. Their genetic, pharmacologic, immune, and metabolic experiments connect enzalutamide exposure with stronger MDSC-mediated suppression and reduced myeloid mitochondrial respiration, clarifying one mechanism of resistance to antiandrogen therapy.
-
Marein Reverses ABCG2-Mediated Mitoxantrone Resistance
2026-08-21
The reference study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of ABCG2-mediated drug efflux. By increasing intracellular accumulation of transporter-substrate drugs, including Mitoxantrone, marein restores chemosensitivity in ABCG2-expressing resistant cancer cells and provides a mechanistic framework for combination studies.
-
EVMPs Enable Extrahepatic mRNA Delivery
2026-08-20
The reference study presents a self-assembling enveloped virus-mimicking particle (EVMP) that combines a programmable virus-mimicking peptide with tissue-selective phospholipid envelopes. Its optimized formulation delivered mRNA to lung and spleen tissues and reduced metastatic lung tumor progression after loading with IL-12 mRNA, offering a preclinical strategy for moving mRNA therapeutics beyond hepatic targeting.
-
HyperScribe T7 Cy5 RNA Probes for N LLPS
2026-08-20
The HyperScribe T7 High Yield Cy5 RNA Labeling Kit supports tunable fluorescent RNA probe synthesis for in situ hybridization and Northern analysis. This article connects probe design to SARS-CoV-2 nucleocapsid RNA condensation while clarifying what Cy5 imaging can—and cannot—demonstrate about liquid–liquid phase separation.
-
GDC-0941 PI3K Inhibition: Workflow and Uses
2026-08-19
GDC-0941 supports mechanism-first studies of PI3K/Akt signaling, from rapid phospho-Akt suppression to longer-term cancer cell proliferation inhibition. This guide translates its biochemical selectivity and published response benchmarks into practical assay workflows, orthogonal apoptosis testing, and cautious combination-study design.
-
Grazoprevir Hydrate: From Target to Assay
2026-08-19
Grazoprevir hydrate, also known as MK-5172 hydrate, is a potent HCV NS3/4A protease inhibitor. This article connects its molecular pharmacology with genotype-aware assay design, pharmacokinetic interpretation, and translational decision-making.
-
GDC-0068 (RG7440) Pan-AKT Inhibitor
2026-08-18
A practical, scenario-driven guide to using GDC-0068 (RG7440) Pan-AKT Inhibitor, SKU A3006, in cell viability, proliferation, and pathway studies. It covers target biology, stock preparation, dose selection, interpretation of phospho-AKT data, and evidence-based product evaluation.
-
Balsalazide for Active Ulcerative Colitis: Evidence Review
2026-08-18
The reference paper evaluates balsalazide as a colon-targeted 5-aminosalicylate prodrug designed to release active 5-ASA through bacterial azoreduction. Its review of clinical and pharmacological evidence indicates effective remission induction in mild-to-moderate active ulcerative colitis, with a favorable tolerability profile and potentially faster symptom improvement than mesalamine.
-
Novobiocin: From Susceptibility Data to Assay Design
2026-08-17
Novobiocin is an aminocoumarin antibiotic whose assay value depends on target biology, isolate phenotype, and endpoint selection. This evidence-driven guide translates staphylococcal susceptibility data into practical antibacterial, antiparasitic, antiviral, and resistance-research workflows.